UY30094A1 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
UY30094A1
UY30094A1 UY30094A UY30094A UY30094A1 UY 30094 A1 UY30094 A1 UY 30094A1 UY 30094 A UY30094 A UY 30094A UY 30094 A UY30094 A UY 30094A UY 30094 A1 UY30094 A1 UY 30094A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
manufacture
relates
cancer
activity
Prior art date
Application number
UY30094A
Other languages
English (en)
Inventor
Qibin Su
Jamal Carlos Saeh
Gurmit Grewal
Tracey Deegan
Scott Cowen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30094A1 publication Critical patent/UY30094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos químicos de fórmula (I) y (II): o sus sales farmac{ueitcamente aceptables, que presentan actividad antagonista de Edg-1 y son, por lo tanto, útiles por su actividad anti-cáncer y, de esta forma, en métodos de tratamiento del cuerpo humano o animal. La invención también se refiere a procesos para la fabricación de dichos compuestos químicos, a composiciones farmacéuticas que los contienen y a su uso en la fabricación de medicamentos para la producción de un efecto anti-cáncer en un animal de sangre caliente tal como el hombre.
UY30094A 2006-01-17 2007-01-15 Compuestos químicos UY30094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75943806P 2006-01-17 2006-01-17

Publications (1)

Publication Number Publication Date
UY30094A1 true UY30094A1 (es) 2007-08-31

Family

ID=38066557

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30094A UY30094A1 (es) 2006-01-17 2007-01-15 Compuestos químicos

Country Status (13)

Country Link
US (1) US20100197749A1 (es)
EP (1) EP1979332A1 (es)
JP (1) JP2009523774A (es)
KR (1) KR20080094913A (es)
CN (1) CN101370794A (es)
AR (1) AR059138A1 (es)
AU (1) AU2007206746A1 (es)
BR (1) BRPI0706402A2 (es)
CA (1) CA2636120A1 (es)
IL (1) IL192591A0 (es)
TW (1) TW200736234A (es)
UY (1) UY30094A1 (es)
WO (1) WO2007083089A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
CN101415691B (zh) 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
US7994204B2 (en) 2006-02-06 2011-08-09 Taisho Pharmaceutical Co., Ltd Binding inhibitor of sphingosine-1-phosphate
WO2008059238A1 (en) * 2006-11-17 2008-05-22 Astrazeneca Ab Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer
PL2177512T3 (pl) * 2007-08-01 2012-09-28 Taisho Pharmaceutical Co Ltd Inhibitor wiązania S1P1
WO2009019506A1 (en) * 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
HUE030424T2 (en) 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
ES2583630T3 (es) 2008-08-27 2016-09-21 Arena Pharmaceuticals, Inc. Derivados de ácido tricíclico sustituido como agonistas del receptor S1P1 útiles en el tratamiento de trastornos autoinmunes e inflamatorios
PT2481725E (pt) * 2009-09-25 2015-05-21 Astellas Pharma Inc Composto de amida substituído
CN103221391B (zh) 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
US9245267B2 (en) 2010-03-03 2016-01-26 Visa International Service Association Portable account number for consumer payment account
JP2013521301A (ja) 2010-03-03 2013-06-10 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体修飾物質およびその結晶形の調製のためのプロセス
JP5776695B2 (ja) * 2010-09-24 2015-09-09 アステラス製薬株式会社 置換アミド化合物
CA2810706C (en) * 2010-09-24 2018-06-12 Astellas Pharma Inc. Substituted amide compound
US20150368213A1 (en) * 2014-06-20 2015-12-24 The University of Montana, Missoula, MT Novel Inhibitors of System Xc-
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
BR112018074646A2 (pt) * 2016-05-31 2019-03-06 Taiho Pharmaceutical Co., Ltd. composto de sulfonamida ou sal do mesmo
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
CN106349483A (zh) * 2016-08-14 2017-01-25 衡阳师范学院 一种含有萘甲羧基与邻菲罗啉的多核钙聚合物及其制备方法与应用
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
CA3084030C (en) * 2017-11-29 2023-03-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482896A4 (en) * 2002-03-01 2005-11-23 Merck & Co Inc AMINOALKYLPHOSPHONATES AND ASSOCIATED COMPOUNDS AS EDG RECEPTOR AGONISTS
JP2005531506A (ja) * 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
RU2383536C2 (ru) * 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
EP1757290A1 (en) * 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors

Also Published As

Publication number Publication date
EP1979332A1 (en) 2008-10-15
IL192591A0 (en) 2009-02-11
KR20080094913A (ko) 2008-10-27
AR059138A1 (es) 2008-03-12
WO2007083089A1 (en) 2007-07-26
JP2009523774A (ja) 2009-06-25
CA2636120A1 (en) 2007-07-26
AU2007206746A1 (en) 2007-07-26
CN101370794A (zh) 2009-02-18
BRPI0706402A2 (pt) 2011-03-29
TW200736234A (en) 2007-10-01
US20100197749A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
UY30094A1 (es) Compuestos químicos
UY30282A1 (es) Compuestos quimicos
UY29300A1 (es) Compuestos quimicos
ECSP099322A (es) Compuestos químicos
UY29093A1 (es) Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones.
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY31281A1 (es) Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
NI201500123A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
ECSP10010695A (es) Compuestos de piridina
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY28122A1 (es) Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones
MX2011013869A (es) Agentes antihelminticos y su uso.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120605